A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02283320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small cell lung cancer (NSCLC) who have progressed after treatment of one prior platinum-containing chemotherapy regimen.
Study identification
- NCT ID
- NCT02283320
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2014 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Apr 18, 2016
2014 – 2016
United States locations
- U.S. sites
- 22
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site: #51 | Chandler | Arizona | 85224 | — |
| Investigative Site: #30 | Goodyear | Arizona | 85338 | — |
| Investigative Site: #44 | Phoenix | Arizona | 85016 | — |
| Investigative Site: #41 | Sedona | Arizona | 86336 | — |
| Investigative Site: #58 | Duarte | California | 91010 | — |
| Investigative Site: #47 | La Jolla | California | 92093 | — |
| Investigative Site: #32 | Los Angeles | California | 90048 | — |
| Investigative Site: #50 | San Francisco | California | 94115 | — |
| Investigative Site: #46 | Fort Meyers | Florida | 33916 | — |
| Investigative Site: #53 | Newnan | Georgia | 30265 | — |
| Investigative Site: #56 | Savannah | Georgia | 31405 | — |
| Investigative Site: #35 | Zion | Illinois | 60099 | — |
| Investigative Site: #36 | Las Vegas | Nevada | 89119 | — |
| Investigative Site: #60 | Portland | Oregon | 97239 | — |
| Investigative Site: #34 | Pittsburgh | Pennsylvania | 15232 | — |
| Investigative Site: # 59 | Pittsburgh | Pennsylvania | 15240 | — |
| Investigative Site: #39 | Amarillo | Texas | 79106 | — |
| Investigative Site: #42 | Dallas | Texas | 75231 | — |
| Investigative Site: 38 | Dallas | Texas | 75237 | — |
| Investigative Site: #40 | Blacksburg | Virginia | 24060 | — |
| Investigative Site: #45 | Vancouver | Washington | 98684 | — |
| Investigative Site: #37 | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02283320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2016 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02283320 live on ClinicalTrials.gov.